The drug and gene delivery devices market size was estimated at USD 460.9 billion in 2022 and is expected to surpass around USD 932.4 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 7.3% during the forecast period 2023 to 2032.
Key Takeaways:
Drug And Gene Delivery Devices Market Report Scope
Report Attribute | Details |
Market Size in 2023 | USD 494.55 Billion |
Market Size by 2032 | USD 932.4 Billion |
Growth Rate From 2023 to 2032 | CAGR of 7.3% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Segments Covered | Delivery Type, Method, Vector, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Key Companies Profiled | Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, Uniqure NV |
Growing efforts towards formulating dosage forms that would help in maximizing the bioavailability of the drug at the target site while increasing patient convenience are driving the global market growth. The introduction of novel drug delivery systems such as subdermal implants that are available in different forms such as rings and patches are expected to aid in the industry growth.
The evolution of the drug delivery systems is directly attributed to changing preferences by patients as well as healthcare professionals. A few of the many advancements include
Drug And Gene Delivery Devices Market Trends
The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases, such as cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.
The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases like cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the major players in the field of genomics are increasing their efforts in research and development. The demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.
The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. Players in the injectable medicine market are getting regulatory approval for various treatments used in syringes to increase their market share over the forecast period.
The market for drug delivery devices is anticipated to hinder due to regulatory approvals uncertainties. Investments in new product innovations are pushed to the limit due to the possibility of revenue loss from delays in product releases and increased costs paid due to strict regulatory processes, which is impacting the expansion of the drug and gene delivery devices market.
Technological developments in injectable medical equipment have accelerated patient acceptance of self-injectable devices. Since the diabetic patient has to inject insulin regularly, the growing diabetic population is driving the expansion of this market. The rise in popularity of self-injectors, pen-injectors, needle-free injectors, and auto-injectors has made it possible for patients to administer medications at home without needing medical help. The drug and gene delivery device market is anticipated to be significantly impacted by all of these factors, which is expected to increase demand for injectable products over the forecast period.
Delivery Type Insights
Based on delivery type, the oral segment dominated the global drug and gene delivery devices market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. The oral drug delivery is the most convenient and most popular route of administration all over the globe. It is economical, pain-free, and self-administered type of delivery where no sterile precautions are involved. Moreover, the development of various therapeutics that can identify the affected cell and can treat that cell without harming the normal cells is exponentially boosting the growth of this segment. Therefore, the rapid growth of the biosimilar, targeted therapeutics, and gene therapies had positively impacted the market growth in the past few years.
On the other hand, the injectable is estimated to be the most opportunistic segment during the forecast period. The technological advancements in the injectable devices has propelled the adoption of the self-injectable devices among the patients. The rising number of diabetic population is fostering the growth of this segment as the diabetic patient need to regularly inject insulin. The increasing popularity of the self-injectors, needle-free injectors, pen-injectors, and auto-injectors has allowed the patients to conveniently administer drugs from the convenience of their home, eliminating the medical assistance. All these factors are estimated to have a significant impact on the drug and gene delivery devices market and will foster the demand for the injectable segment in the forthcoming years.
Methods Insights
Based on the method used, gene delivery system is segmented as in situ and ex vivo. Most of the currently approved drugs act by in situ methods. Thus, the in situ segment is currently dominating the industry with the largest share.
High focus on the in situ methods owing to its ease of performance is expected to make it the fastest growing segment in the space. However, the segment growth is expected to impede the low efficiency of transduction procedures.
Vector Insights
Viral vectors currently dominate the gene delivery systems market with 4 approved drugs. More than 80% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection. Thus, the viral segment is expected to remain dominant throughout the forecast period.
Viral vectors enable complex procedures involved in transfection procedures such as gene gun, magnetofection, ultrasound, and hydrodynamic. In addition, it has increased the success rate of the gene transfer as compared to its counterpart techniques
Regional Insights
North America captured the largest market share in 2022. The presence of a large number of key players and high adoption rate of the advanced methods are the factors driving the industry growth in the region. In addition, high investment in R&D by the U.S. government and industry participants is augmenting the industry growth of the region.
Asia Pacific is expected to show a lucrative growth rate during the forecast period owing to factors such as growing awareness about the novel systems as well as the influx of the international industry players to seek opportunities in the untapped market in the region.
Recent Development
Some of the prominent players in the Drug And Gene Delivery Devices Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Drug And Gene Delivery Devices market.
By Delivery Type
By Method
By Vector
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug and Gene Delivery Devices Market
5.1. COVID-19 Landscape: Drug and Gene Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug and Gene Delivery Devices Market, By Delivery
8.1. Drug and Gene Delivery Devices Market, by Delivery Type, 2023-2032
8.1.1. Oral
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Ocular
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Inhalation
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Nasal
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Injectable
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Transdermal
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Topical
8.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Drug and Gene Delivery Devices Market, By Method
9.1. Drug and Gene Delivery Devices Market, by Method, 2023-2032
9.1.1. In Situ
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Ex Vivo
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Drug and Gene Delivery Devices Market, By Vector
10.1. Drug and Gene Delivery Devices Market, by Vector, 2023-2032
10.1.1. Viral Vector
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Non-Viral Vector
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Drug and Gene Delivery Devices Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.1.2. Market Revenue and Forecast, by Method (2020-2032)
11.1.3. Market Revenue and Forecast, by Vector (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Vector (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.2.2. Market Revenue and Forecast, by Method (2020-2032)
11.2.3. Market Revenue and Forecast, by Vector (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Vector (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Method (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Vector (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Method (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Vector (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.3.2. Market Revenue and Forecast, by Method (2020-2032)
11.3.3. Market Revenue and Forecast, by Vector (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Vector (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Method (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Vector (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Method (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Vector (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Vector (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Method (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Vector (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Method (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Vector (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.5.3. Market Revenue and Forecast, by Vector (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Method (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Vector (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Method (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Vector (2020-2032)
Chapter 12. Company Profiles
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson and Johnson Private Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Becton, Dickinson and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Uniqure NV
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms